Arsanis Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Arsanis Inc
TickerXFOR
CIK #0001501697
CUSIP98420X103
SectorLife Sciences - Biological Products, (No Disgnostic Substances)
Address890 Winter Street, Suite 230, Waltham, MA 02451
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
X4 Pharmaceuticals Inc 2025-08-25 85.0 M Exemption: 506(b) · Duration: One year or less · Commission: $3,300,000 · Revenue: Decline to Disclose
Arsanis Inc 2017-12-04 20.0 M Exemption: 506(c) · Duration: One year or less · Commission: $1,400,000 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001501697] 10-K
[0001501697] 10-Q
[0001501697] 3
[0001501697] 4
[0001501697] 8-K
[0001501697] D
[0001501697] SC 13D
[0001501697] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Saturn V Capital Management LP X4 Pharmaceuticals Inc [2026-02-17] 0.0
Morgan Stanley X4 Pharmaceuticals Inc [2026-02-12] 0.0
Nantahala Capital Management LLC X4 Pharmaceuticals Inc [2025-11-14] 0.0
FMR LLC X4 Pharmaceuticals Inc [2025-11-07] 0.0
Perceptive Advisors LLC X4 Pharmaceuticals Inc [2025-11-03] 0.0
Empery Asset Management LP X4 Pharmaceuticals Inc [2025-10-21] 0.0
Coastlands Capital LP X4 Pharmaceuticals Inc [2025-10-03] 0.0
Biotechnology Value Fund L P X4 Pharmaceuticals Inc [2025-08-20] 0.0
Deep Track Capital LP X4 Pharmaceuticals Inc [2025-08-19] 0.0
Coastlands Capital LP X4 Pharmaceuticals Inc [2025-08-18] 0.0
Trails Edge Capital Partners LP X4 Pharmaceuticals Inc [2025-08-18] 0.0
Bain Capital Life Sciences Fund LP X4 Pharmaceuticals Inc [2025-08-13] 0.0
BlackRock Inc X4 Pharmaceuticals Inc [2024-11-08] 6.7
BlackRock Inc X4 Pharmaceuticals Inc [2024-10-22] 6.7
Acorn BioVentures LP X4 Pharmaceuticals Inc [2024-02-14] 4.8
BlackRock Inc X4 Pharmaceuticals Inc [2024-01-31] 5.0
Millennium Management LLC X4 Pharmaceuticals Inc [2023-06-16] 5.2
Empery Asset Management LP X4 Pharmaceuticals Inc [2023-01-13] 5.12
Growth Equity Opportunities 18 VGE LLC X4 Pharmaceuticals Inc [2022-07-19] 0.9
Lincoln Park Capital Fund LLC X4 Pharmaceuticals Inc [2022-01-19] 6.44
Point72 Asset Management LP X4 Pharmaceuticals Inc [2021-11-17] 5.6
Hirschman Orin X4 Pharmaceuticals Inc [2021-06-29] 6.2
BlackRock Inc X4 Pharmaceuticals Inc [2021-02-02] 6.3
Ikarian Capital LLC X4 Pharmaceuticals Inc [2020-12-30] 5.1
RA Capital Management LP X4 Pharmaceuticals Inc [2020-02-14] 0.9
EcoR1 Capital LLC X4 Pharmaceuticals Inc [2019-12-17] 7.2
Bain Capital Life Sciences Fund LP X4 Pharmaceuticals Inc [2019-12-09] 9.99
FMR LLC X4 Pharmaceuticals Inc [2019-05-10] 0.0
Biotechnology Value Fund L P X4 Pharmaceuticals Inc [2019-04-23] 6.4
Cormorant Asset Management LP X4 Pharmaceuticals Inc [2019-04-22] 5.93
OrbiMed Advisors LLC X4 Pharmaceuticals Inc [2019-04-19] 0.8
Flynn James E X4 Pharmaceuticals Inc [2019-04-16] 6.69
Ragan Paula X4 Pharmaceuticals Inc [2019-03-22] 11.0
Bill & Melinda Gates Foundation X4 Pharmaceuticals Inc [2019-03-15] 1.8
X4 Pharmaceuticals Inc Arsanis Inc [2018-12-06] 48.2
SVLSF V LLC Arsanis Inc [2018-02-14] 6.5
Bill & Melinda Gates Foundation Arsanis Inc [2018-02-13] 5.1
FMR LLC Arsanis Inc [2017-12-11] 0.0
OrbiMed Advisors LLC Arsanis Inc [2017-11-30] 13.07
New Enterprise Associates 16 LP Arsanis Inc [2017-11-29] 14.6
Polaris Venture Partners V LP Arsanis Inc [2017-11-29] 13.2
Form 3/4/5 Filer 2011 - 2026
Gold Kelly
X4 Pharmaceuticals Inc
Kirske David
Bridger Gary
Wyzga Michael S
de Craecker Francoise
Stewart Murray
Volpone John
Craig Adam R
Thoren Natasha Fay
Woods Keith
McGirr David W J
Baldry Mark
Arbet-Engels Christophe
DiBiase Mary
Ragan Paula
Mostafa Adam S
Taveras Arthur
Lawton Alison Frances
Aliski William
Meisner Derek M
Cadavid Diego
Russo Rene
Skerlj Renato
Kelley Lynne E
Blech Isaac
Gray Michael
Behbahani Ali
Chang Carmen
Schulman Amy W
McGuire Terrance
Ross Michael Jay
Nessi Claudio
Gordon Carl L
Gerngross Tillman U
Clark William D
Nagy Eszter
Mantus David
Stevens Anthony Chris
Sakoda Jon
Barris Peter J
Baskett Forest
Florence Anthony A Jr
Makhzoumi Mohamad
Mott David M
Puttagunta Chetan
NEA Partners 16 LP
New Enterprise Associates 16 LP
NEA 16 GP LLC
Sandell Scott D
Sonsini Peter W
Viswanathan Ravi
EMBL Technology Fund II GmbH & Co KG
Muhlenbeck Frank
Herr Stefan
Adams Jan
EMBL Ventures Verwaltungs GmbH
NeoMed Innovation V LP
NeoMed Innovation V Ltd
NeoMed Management Jersey Ltd
Alphabet Inc
GV 2016 LP
GV 2016 GP LLC
GV 2016 GP LP
Anna-Maria & Stephen Kellen Foundation Inc
Maris William J
Section 32 GP 1 LLC
Section 32 Fund 1 LP
SV Life Sciences Fund V Strategic Partners LP
SV Life Sciences Fund V LP
SVLSF V LLC
SV Life Sciences Fund VI Strategic Partners LP
SV Life Sciences Fund VI LP
Isaly Samuel D
OrbiMed Advisors LLC
OrbiMed Capital GP IV LLC
Polaris Venture Partners V LP
Polaris Venture Partners Entrepreneurs' Fund V LP
Polaris Venture Management Co V LLC
Flint Jonathan A
Polaris Venture Partners Founders' Fund V LP
Polaris Venture Partners Special Founders' Fund V LP
Alexandria Venture Investments LLC
Bill & Melinda Gates Foundation
SVLSF VI LLC
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
de Craecker Francoise
Stock Option (right to buy) · derivative
2026-01-01 Grant 110,000 $0.00
Bridger Gary
Stock Option (right to buy) · derivative
2026-01-01 Grant 110,000 $0.00
Stewart Murray
Stock Option (right to buy) · derivative
2026-01-01 Grant 110,000 $0.00
Wyzga Michael S
Stock Option (right to buy) · derivative
2026-01-01 Grant 110,000 $0.00
Volpone John
Stock Option (right to buy) · derivative
2025-10-29 Grant 2,329,154 $0.00
Kirske David
Stock Option (right to buy) · derivative
2025-10-29 Grant 1,552,769 $0.00
Craig Adam R
Stock Option (right to buy) · derivative
2025-10-29 Grant 2,329,154 $0.00
Craig Adam R
Common Stock
2025-10-23 Buy 86,206 $2.90 249,997
Kirske David
Stock Option (right to buy) · derivative
2025-08-14 Grant 352,800 $0.00
Craig Adam R
Common Stock
2025-08-14 Grant 289,881 $0.00
Volpone John
Common Stock
2025-08-14 Grant 289,881 $0.00
Craig Adam R
Stock Option (right to buy) · derivative
2025-08-14 Grant 529,201 $0.00
Volpone John
Stock Option (right to buy) · derivative
2025-08-14 Grant 529,201 $0.00
Kirske David
Common Stock
2025-08-14 Grant 193,254 $0.00
Craig Adam R
Stock Option (right to buy) · derivative
2025-08-12 Grant 1,609,873 $0.00
Volpone John
Stock Option (right to buy) · derivative
2025-08-12 Grant 1,609,873 $0.00
Kirske David
Stock Option (right to buy) · derivative
2025-08-12 Grant 1,073,249 $0.00
Wyzga Michael S
Common Stock
2025-06-09 Grant 1,500 $0.00
Woods Keith
Common Stock
2025-06-09 Grant 1,500 $0.00
Bridger Gary
Common Stock
2025-06-09 Grant 1,500 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 84 98,479,119
2025-12-31 79 89,554,970
2025-09-30 43 16,287,304
2025-06-30 53 2,935,220
2025-03-31 97 99,183,104
2024-12-31 92 100,351,339
2024-09-30 100 100,930,124
2024-06-30 102 105,178,886
2024-03-31 100 106,180,108
2023-12-31 95 104,045,346
2023-09-30 92 112,687,167
2023-06-30 100 118,478,715
Form 13F Holdings
Firm Period DFND Voting Shares
Pettinga Financial Advisors LLC [2026-06-30] SOLE 0 10,000
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com